Market revenue in 2021 | USD 123.3 million |
Market revenue in 2030 | USD 925.2 million |
Growth rate | 25.1% (CAGR from 2021 to 2030) |
Largest segment | Serum biomarkers |
Fastest growing segment | Hepatic Fibrosis Biomarkers |
Historical data covered | 2018 - 2020 |
Base year for estimation | 2021 |
Forecast period covered | 2022 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Serum Biomarkers, Hepatic Fibrosis Biomarkers, Apoptosis Biomarkers, Oxidative Stress Biomarkers |
Key market players worldwide | Genfit SA, Siemens AG, Quest Diagnostics Inc, AstraZeneca PLC, Meridian Bioscience, Labcorp Holdings Inc, Pfizer Inc, Bristol-Myers Squibb Co |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to non-alcoholic steatohepatitis biomarkers market will help companies and investors design strategic landscapes.
Serum biomarkers was the largest segment with a revenue share of 32.85% in 2021. Horizon Databook has segmented the Asia Pacific non-alcoholic steatohepatitis biomarkers market based on serum biomarkers, hepatic fibrosis biomarkers, apoptosis biomarkers, oxidative stress biomarkers covering the revenue growth of each sub-segment from 2018 to 2030.
Asia Pacific is expected to witness significant growth due to the local presence of leading biomarker companies and an increase in R&D investment. There has been an increase in R&D investments in China, India, and Japan, which has accelerated the development of NASH biomarkers.
Moreover, the cost of clinical trials in developing countries is lower than that in developed countries. In addition, there has been an increase in the population and disposable income in developing countries such as India, Japan, & China.
The high incidence of NASH in this region has increased the demand for biomarkers for diagnostic purposes, government funding for R&D of biomarkers, and healthcare expenditure. These factors are expected to boost the market.
Horizon Databook provides a detailed overview of continent-level data and insights on the Asia Pacific non-alcoholic steatohepatitis biomarkers market , including forecasts for subscribers. This continent databook contains high-level insights into Asia Pacific non-alcoholic steatohepatitis biomarkers market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account